U.S. Paper and Forestry Products Stock News

If you are asking whether Amprius Technologies at US$16.12 is still attractively priced or already running ahead of itself, the next sections walk through the key numbers you need to weigh that up. The stock has been volatile recently, with an 11.4% decline over the past 7 days, a 50.2% gain over 30 days, an 84.4% return year to date and a very large 1 year return of 473.7%. Recent coverage has focused on Amprius as a high growth, high volatility name in the Electrical industry, and those...

In March 2026, Ligand Pharmaceuticals expanded its leadership team by appointing healthcare investors Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development, while broadening Lauren Hay’s role to Vice President of Portfolio Strategy and Investments to focus on royalty financing and portfolio optimization. Around the same time, Chief Financial Officer Octavio Espinoza sold 3,057 shares for about US$688,000 under a prearranged 10b5-1 plan, alongside company...

In March 2026, Ingles Markets and activist investor Summer Road LLC entered a heated proxy fight, filing competing proxy statements over board seats and a non-binding executive pay proposal ahead of the April 30, 2026 annual meeting. This contest highlights growing shareholder pressure on Ingles Markets’ governance and executive compensation practices, putting board composition and accountability under closer scrutiny. Next, we will examine how this proxy contest over board representation...

Recent share performance and business context MongoDB (MDB) has drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past week, month and past 3 months, alongside a negative year to date move. This share price backdrop sits against annual revenue of US$2.46b and a reported net loss of US$71.15m, raising questions about how investors should weigh growth in its database platform against profitability and valuation today. See our...

Regeneron Pharmaceuticals (REGN) is back in focus after Japan’s Ministry of Health, Labour and Welfare approved Dupixent for adults with moderate to severe bullous pemphigoid, expanding the drug’s footprint in a rare inflammatory skin disease. See our latest analysis for Regeneron Pharmaceuticals. Even with the positive Dupixent news, Regeneron’s short term share price return has been muted. The 7 day share price return is 0.66% and the 30 day share price return reflects a 5.62% decline. The...

Dollar General announced in March 2026 that Jerry “JJ” Fleeman Jr., a veteran Ahold Delhaize USA executive, will succeed Todd Vasos as CEO and join the Board on January 1, 2027, with Vasos remaining as a Senior Advisor through April 2, 2027 and continuing as a director thereafter. This leadership transition brings deep grocery and digital expertise into a business already reshaped under Vasos by DG Fresh, pOpshelf, international expansion, and enhanced delivery and loyalty programs. Next,...

Wondering if Huntington Ingalls Industries at around US$381.79 is still offering value after a strong run, or if the easy gains are already behind it. The stock has seen a 6.4% decline over the past 7 days and a 14.1% decline over the past 30 days, while the 1 year return stands at 89.4% and the 3 year and 5 year returns are 96.7% and 108.6% respectively. Recent attention on the company has centered on its role in U.S. defense and shipbuilding programs. This often keeps investors focused on...

Commerce Bancshares stock snapshot after recent performance Commerce Bancshares (CBSH) shares recently closed at US$48.07, with the stock showing a 1 day return of 1.88% and a past month decline of 5.73%, extending to 8.75% over the past 3 months. See our latest analysis for Commerce Bancshares. Stepping back, the recent softness in the 1 month share price return of 5.73% and 3 month share price return of 8.75% sits alongside a 1 year total shareholder return of 16.49%. This may indicate...

Recent performance snapshot Hims & Hers Health (HIMS) has drawn investor attention after a mixed run, with the share price near US$19.38 and returns ranging from a 33% gain over the past month to a 43% decline over the past 3 months. See our latest analysis for Hims & Hers Health. The recent pullback, including a 7.1% 1 day share price decline and weaker year to date share price return, sits against a much stronger 3 year total shareholder return of 95.4%. This suggests that momentum has...

Norwegian Cruise Line Holdings (NYSE:NCLH) has entered a cooperation agreement with Elliott Investment Management. The company is appointing five new directors to the board, including leaders from travel, finance, and investment sectors. CEO John Chidsey is also becoming Board Chairman as part of the governance changes. Norwegian Cruise Line Holdings runs a global cruise operation, competing with other large operators for leisure travel demand. The cruise sector has been influenced by...

Why Bitdeer’s latest moves matter for BTDR stock Bitdeer Technologies Group (BTDR) has put fresh attention on its stock with two developments: a new SEALMINER DL1 Air Scrypt mining machine and unaudited February 2026 operating metrics showing expanded hash rate and mining activity. See our latest analysis for Bitdeer Technologies Group. The latest product launch and operating update come after a mixed year for investors. The share price is US$8.37, with a 1 month share price return of 8.7%,...

Why CSX’s upcoming earnings and locomotive upgrade matter now CSX (CSX) heads into its April 22 first quarter earnings report with attention on a recent US$670 million agreement with Wabtec to modernize its Evolution Series locomotive fleet for fuel efficiency and reliability gains. See our latest analysis for CSX. CSX’s 1-year total shareholder return of 38.35% and 3-year total shareholder return of 38.37% sit against a 9.37% year to date share price return and an 8.03% 90 day share price...

PHINIA stock at a glance PHINIA (PHIN) is catching investor attention after recent share price swings, with a last close at $67.11 and returns ranging from a 7% gain over the past week to a 7.6% decline over the month. See our latest analysis for PHINIA. Recent moves have been choppy, with a 7% 7 day share price return following a 7.6% 30 day share price decline. At the same time, the 1 year total shareholder return of 58.9% points to momentum that has been strong over a longer stretch. If...

Privosegtor data presentation puts Oculis Holding (OCS) in focus Oculis Holding (NasdaqGM:OCS) is coming into focus after announcing that ACUITY Phase 2 data for its investigational therapy Privosegtor in acute optic neuritis will be presented at the NANOS 2026 meeting. See our latest analysis for Oculis Holding. At a share price of $24.69, Oculis has seen a 16.05% 1 month share price decline after strong longer term momentum, including a 23.45% 3 month share price return and a 232.30% 3 year...

What Semtech’s Recent Share Performance Tells You Semtech (SMTC) has drawn investor attention after a recent pullback, with the share price down 2.7% over the past day and about 20% over the past month, despite strong longer term returns. See our latest analysis for Semtech. The recent 30 day share price return of a 20% decline, alongside a 4.1% year to date share price decline, contrasts with a 1 year total shareholder return of 105.9%. This suggests that momentum has cooled after a strong...

Diodes (DIOD) is back on investor radar after expanding its PowerDI8080-5 automotive-compliant N-channel MOSFET line with a new ultra-low RDS(ON) 100V device aimed at demanding electric vehicle systems. See our latest analysis for Diodes. The product launch arrives after a strong 90 day share price return of 36.35% and a 1 year total shareholder return of 57.43%. However, the 3 and 5 year total shareholder returns remain negative, suggesting recent momentum is building off a weaker long term...

Recent price moves and business snapshot Titan America (TTAM) has drawn investor attention after recent price swings, with the share price at $14.82 and returns ranging from a 4.4% gain over the past week to an 18.2% decline over the month. For context, Titan America SA generates US$1.66b in revenue, all from the United States, and reports net income of US$185.44m across its Florida and Mid Atlantic business segments. See our latest analysis for Titan America. The recent 18.2% 1 month share...

GLOBALFOUNDRIES (GFS) has moved into the spotlight after filing multiple U.S. patent infringement lawsuits against Tower Semiconductor, a legal step that puts its manufacturing know how and intellectual property protections front and center for investors. See our latest analysis for GLOBALFOUNDRIES. The legal action lands at a time when the share price is US$42.94, with a 19.78% 90 day share price return and a 16.40% 1 year total shareholder return, contrasting with a 3 year total shareholder...

For investors wondering if CACI International at around US$563 per share still offers value after a strong run, this article explains what the current price may be implying about the stock. The share price is US$563.67 after a 7% decline over the last week and a 7.6% decline over the last month. Despite this, the 1 year return is 51%, and the 3 year and 5 year returns are 90.2% and 126.7% respectively. Recent coverage has focused on the stock's strong multi year performance and the pullback...

If you are wondering whether Archrock's recent share price puts it on sale or already fully priced, it helps to step back and look carefully at what the current valuation actually reflects. At a last close of US$35.52, the stock has returned 0.5% over the past month, 33.4% year to date and 38.7% over the last year. The 3 year and 5 year returns are very large at more than 7x and around 7x respectively, which naturally raises questions about how much future upside or risk is now baked...

WD-40 stock moves after recent share performance WD-40 (WDFC) has drawn fresh attention after recent share performance, with the stock down about 2% over the past day, 6% over the past week, and 16% over the past month. See our latest analysis for WD-40. That recent slide sits against a mixed backdrop, with a 1 year total shareholder return of about 15% decline but a 3 year total shareholder return of roughly 19% gain, so recent momentum looks weaker than the longer term picture. If WD-40’s...

If you are wondering whether Vera Therapeutics at around US$38.86 is priced purely on its story or still leaves some value on the table, this article walks through what the current share price actually implies. The stock has had a mixed run, with a 4.1% decline over the past week and a 4.7% decline over the past month, yet it still shows a 45.9% return over the last year and a very large return over three years. Recent attention on Vera Therapeutics has focused on its position in the biotech...

Earlier this month, Onto Innovation Inc. launched its Dragonfly G5 inspection and metrology system, securing double-digit orders from a high bandwidth memory manufacturer for HBM4 ramp, with shipments scheduled to begin in the second quarter of 2026. The Dragonfly G5’s finer defect sensitivity, higher throughput, and expanded machine learning capabilities highlight how Onto Innovation is deepening its role in advanced semiconductor packaging process control. Next, we’ll explore how the...

WeRide, listed as NasdaqGM:WRD, has launched a share repurchase program covering up to 10% of its issued share capital. In addition, the buyback follows the company’s recent entry into Slovakia to roll out what it calls the country’s first autonomous vehicle initiative. WeRide also presented its next generation Robotaxi at NVIDIA GTC 2026, highlighting its technical partnership and product roadmap. For anyone tracking autonomous driving, WeRide sits at the intersection of software, hardware...